Literature DB >> 30539249

Serum tumor markers and testicular germ cell tumors: a primer for radiologists.

Colin Marshall1, Michael Enzerra2, Amir Ata Rahnemai-Azar1, Nikhil H Ramaiya1.   

Abstract

Serum tumor markers (STMs) play a critical role in the diagnosis, staging and follow-up of both seminomatous and nonseminomatous testicular germ cell neoplasms. Levels of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH), especially those measured after orchiectomy, also have implications for patient prognosis. Given that testicular germ cell tumors represent the most common solid tumor in men aged 20-34, radiologists must have familiarity with the clinical utilization and implications of these STMs. This article will review the classical patterns of STM elevation most commonly seen in pure seminomatous and nonseminomatous germ cell tumors while also providing case-based examples highlighting the importance of STM correlation with imaging. The role of STMs in clinical staging and disease surveillance will also be discussed.

Entities:  

Keywords:  Biomarkers; Radiologists; Radiology; Seminoma/diagnosis; Testicular germ cell tumor; Testicular neoplasms; Tumor

Mesh:

Substances:

Year:  2019        PMID: 30539249     DOI: 10.1007/s00261-018-1846-z

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  2 in total

1.  Profiling of Serum Extracellular Vesicles Reveals miRNA-4525 as a Potential Biomarker for Advanced Renal Cell Carcinoma.

Authors:  Yuka Muramatsu-Maekawa; Kyojiro Kawakami; Yasunori Fujita; Manabu Takai; Daiki Kato; Keita Nakane; Taku Kato; Tomohiro Tsuchiya; Takuya Koie; Yuri Miura; Masafumi Ito; Kosuke Mizutani
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

2.  A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.

Authors:  Costantine Albany; Zeeshan Fazal; Ratnakar Singh; Emmanuel Bikorimana; Nabil Adra; Nasser H Hanna; Lawrence H Einhorn; Susan M Perkins; George E Sandusky; Brock C Christensen; Harold Keer; Fang Fang; Kenneth P Nephew; Michael J Spinella
Journal:  Cancer Med       Date:  2020-11-01       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.